Bionano Genomics Stock Total Asset

BNGO Stock

USD 0.88 0.01 1.15%

Bionano Genomics fundamentals help investors to digest information that contributes to Bionano Genomics' financial success or failures. It also enables traders to predict the movement of Bionano Stock. The fundamental analysis module provides a way to measure Bionano Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bionano Genomics stock.

	Last Reported	Projected for Next Year
Total Assets	214.4 M	142.9 M
Intangibles To Total Assets	0.16	0.18

As of the 1st of May 2024, Intangibles To Total Assets is likely to grow to 0.18, while Total Assets are likely to drop about 142.9 M.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Bionano Genomics Company Total Asset Analysis

Bionano Genomics' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Total Asset

Tangible Assets

+

Intangible Assets

More About Total Asset | All Equity Analysis

Current Bionano Genomics Total Asset

214.4 M

Most of Bionano Genomics' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bionano Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Bionano Total Asset Driver Correlations

Understanding the fundamental principles of building solid financial models for Bionano Genomics is extremely important. It helps to project a fair market value of Bionano Stock properly, considering its historical fundamentals such as Total Asset. Since Bionano Genomics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bionano Genomics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bionano Genomics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Long Term Debt Total	Capital Surpluse	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Invested Capital	Net Working Capital	Deferred Long Term Liab	Capital Stock	Good Will	Intangible Assets
Total Assets		0.98	0.95	0.84	0.15	-0.67	0.94	0.72	0.67	0.72	0.86	0.37	0.79	0.98	0.27	0.86	0.73	0.98	0.93	-0.73	0.85	0.78	0.9
Total Stockholder Equity	0.98		0.92	0.77	0.01	-0.58	0.89	0.69	0.59	0.69	0.8	0.23	0.76	0.97	0.18	0.9	0.63	0.98	0.97	-0.71	0.9	0.83	0.83
Net Tangible Assets	0.95	0.92		0.76	0.29	-0.78	0.88	0.72	0.69	0.72	0.93	0.51	0.86	0.96	0.5	0.73	0.79	0.96	0.91	-0.77	0.72	0.57	0.88
Current Deferred Revenue	0.84	0.77	0.76		0.36	-0.7	0.86	0.55	0.59	0.55	0.79	0.5	0.66	0.77	0.3	0.65	0.81	0.77	0.63	-0.64	0.65	0.63	0.89
Net Debt	0.15	0.01	0.29	0.36		-0.72	0.34	0.13	0.53	0.13	0.53	0.92	0.31	0.1	0.77	-0.26	0.71	0.13	-0.09	-0.21	-0.28	-0.24	0.52
Retained Earnings	-0.67	-0.58	-0.78	-0.7	-0.72		-0.8	-0.69	-0.83	-0.69	-0.95	-0.85	-0.88	-0.64	-0.87	-0.4	-0.96	-0.7	-0.49	0.79	-0.38	-0.19	-0.88
Accounts Payable	0.94	0.89	0.88	0.86	0.34	-0.8		0.81	0.83	0.81	0.91	0.52	0.84	0.89	0.43	0.78	0.83	0.93	0.78	-0.8	0.77	0.7	0.96
Long Term Debt	0.72	0.69	0.72	0.55	0.13	-0.69	0.81		0.85	1.0	0.75	0.3	0.85	0.72	0.5	0.71	0.57	0.79	0.62	-0.93	0.69	0.42	0.68
Net Receivables	0.67	0.59	0.69	0.59	0.53	-0.83	0.83	0.85		0.85	0.82	0.56	0.76	0.63	0.69	0.43	0.73	0.71	0.47	-0.75	0.4	0.3	0.79
Long Term Debt Total	0.72	0.69	0.72	0.55	0.13	-0.69	0.81	1.0	0.85		0.75	0.3	0.85	0.72	0.5	0.71	0.57	0.79	0.62	-0.93	0.69	0.42	0.68
Capital Surpluse	0.86	0.8	0.93	0.79	0.53	-0.95	0.91	0.75	0.82	0.75		0.72	0.93	0.83	0.71	0.63	0.94	0.88	0.73	-0.84	0.61	0.44	0.95
Total Liab	0.37	0.23	0.51	0.5	0.92	-0.85	0.52	0.3	0.56	0.3	0.72		0.56	0.34	0.82	0.0	0.86	0.35	0.16	-0.43	-0.01	-0.11	0.67
Short Long Term Debt	0.79	0.76	0.86	0.66	0.31	-0.88	0.84	0.85	0.76	0.85	0.93	0.56		0.78	0.68	0.72	0.83	0.85	0.71	-0.95	0.69	0.39	0.83
Total Current Assets	0.98	0.97	0.96	0.77	0.1	-0.64	0.89	0.72	0.63	0.72	0.83	0.34	0.78		0.28	0.83	0.67	0.98	0.96	-0.72	0.82	0.71	0.84
Short Term Debt	0.27	0.18	0.5	0.3	0.77	-0.87	0.43	0.5	0.69	0.5	0.71	0.82	0.68	0.28		-0.02	0.74	0.34	0.13	-0.59	-0.05	-0.3	0.53
Common Stock	0.86	0.9	0.73	0.65	-0.26	-0.4	0.78	0.71	0.43	0.71	0.63	0.0	0.72	0.83	-0.02		0.45	0.87	0.87	-0.74	1.0	0.86	0.67
Property Plant Equipment	0.73	0.63	0.79	0.81	0.71	-0.96	0.83	0.57	0.73	0.57	0.94	0.86	0.83	0.67	0.74	0.45		0.71	0.52	-0.72	0.44	0.33	0.93
Net Invested Capital	0.98	0.98	0.96	0.77	0.13	-0.7	0.93	0.79	0.71	0.79	0.88	0.35	0.85	0.98	0.34	0.87	0.71		0.94	-0.8	0.85	0.73	0.88
Net Working Capital	0.93	0.97	0.91	0.63	-0.09	-0.49	0.78	0.62	0.47	0.62	0.73	0.16	0.71	0.96	0.13	0.87	0.52	0.94		-0.65	0.86	0.76	0.72
Deferred Long Term Liab	-0.73	-0.71	-0.77	-0.64	-0.21	0.79	-0.8	-0.93	-0.75	-0.93	-0.84	-0.43	-0.95	-0.72	-0.59	-0.74	-0.72	-0.8	-0.65		-0.72	-0.39	-0.74
Capital Stock	0.85	0.9	0.72	0.65	-0.28	-0.38	0.77	0.69	0.4	0.69	0.61	-0.01	0.69	0.82	-0.05	1.0	0.44	0.85	0.86	-0.72		0.87	0.66
Good Will	0.78	0.83	0.57	0.63	-0.24	-0.19	0.7	0.42	0.3	0.42	0.44	-0.11	0.39	0.71	-0.3	0.86	0.33	0.73	0.76	-0.39	0.87		0.61
Intangible Assets	0.9	0.83	0.88	0.89	0.52	-0.88	0.96	0.68	0.79	0.68	0.95	0.67	0.83	0.84	0.53	0.67	0.93	0.88	0.72	-0.74	0.66	0.61

Click cells to compare fundamentals

Bionano Total Asset Historical Pattern

Today, most investors in Bionano Genomics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bionano Genomics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bionano Genomics total asset as a starting point in their analysis.

Bionano Genomics Total Asset

Timeline

Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.

Competition

Predict Bionano Genomics

Total Assets Over Time

Bionano Total Assets

Total Assets

142.92 Million

At this time, Bionano Genomics' Total Assets are very stable compared to the past year.

Based on the latest financial disclosure, Bionano Genomics has a Total Asset of 214.4 M. This is 97.15% lower than that of the Life Sciences Tools & Services sector and 93.11% lower than that of the Health Care industry. The total asset for all United States stocks is 99.27% higher than that of the company.

Bionano Total Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bionano Genomics' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bionano Genomics could also be used in its relative valuation, which is a method of valuing Bionano Genomics by comparing valuation metrics of similar companies.

Bionano Genomics is currently under evaluation in total asset category among related companies.

Bionano Genomics Institutional Holders

Institutional Holdings refers to the ownership stake in Bionano Genomics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bionano Genomics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bionano Genomics' value.

		Shares
Gsa Capital Partners Llp	2023-12-31	86.9 K
Morgan Stanley - Brokerage Accounts	2023-12-31	82.3 K
Archford Capital Strategies, Llc	2024-03-31	69.6 K
Jane Street Group, Llc	2023-12-31	68.6 K
Engineers Gate Manager Lp	2023-12-31	60.2 K
Fmr Inc	2023-12-31	53.6 K
Two Sigma Securities, Llc	2023-12-31	49.4 K
Susquehanna International Group, Llp	2023-12-31	42 K
Headlands Technologies Llc	2023-12-31	38 K
Vanguard Group Inc	2023-12-31	1.9 M
Gmt Capital Corp	2023-12-31	530.3 K

Bionano Fundamentals

	Return On Equity	-1.35
	Return On Asset	-0.33
	Operating Margin	(2.70) %
	Current Valuation	60.94 M
	Shares Outstanding	61.23 M
	Shares Owned By Insiders	0.49 %
	Shares Owned By Institutions	11.96 %
	Number Of Shares Shorted	5.36 M
	Price To Earning	(1.80) X
	Price To Book	0.62 X
	Price To Sales	1.66 X
	Revenue	36.12 M
	Gross Profit	5.95 M
	EBITDA	(125.72 M)
	Net Income	(232.49 M)
	Cash And Equivalents	187.34 M
	Cash Per Share	0.65 X
	Total Debt	87.95 M
	Debt To Equity	0.04 %
	Current Ratio	7.75 X
	Book Value Per Share	2.10 X
	Cash Flow From Operations	(129.7 M)
	Short Ratio	3.29 X
	Earnings Per Share	(6.81) X
	Target Price	6.67
	Number Of Employees	344
	Beta	2.37
	Market Capitalization	54.07 M
	Total Asset	214.4 M
	Retained Earnings	(581.21 M)
	Working Capital	40.09 M
	Current Asset	14.39 M
	Current Liabilities	8.72 M
	Net Asset	214.4 M

About Bionano Genomics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bionano Genomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bionano Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bionano Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bionano Genomics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bionano Genomics' short interest history, or implied volatility extrapolated from Bionano Genomics options trading.

Pair Trading with Bionano Genomics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bionano Stock

0.87

EVOK

Evoke Pharma

Pair Corr

Moving against Bionano Stock

0.7	JAGX	Jaguar Animal Health Financial Report 20th of May 2024	Pair Corr
0.65	ELYM	Eliem Therapeutics Trending	Pair Corr
0.49	DYAI	Dyadic International Financial Report 8th of May 2024	Pair Corr
0.46	HCWB	HCW Biologics	Pair Corr
0.44	KRYS	Krystal Biotech Financial Report 13th of May 2024	Pair Corr

The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.

The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Bionano Genomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bionano Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionano Genomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionano Genomics Stock:

How To Invest In Bionano

Details

Is Bionano Stock a good investment?

Details

What is Bionano Genomics' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Bionano Genomics Piotroski F Score and Bionano Genomics Altman Z Score analysis.

To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.

Note that the Bionano Genomics information on this page should be used as a complementary analysis to other Bionano Genomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for Bionano Stock analysis

When running Bionano Genomics' price analysis, check to measure Bionano Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionano Genomics is operating at the current time. Most of Bionano Genomics' value examination focuses on studying past and present price action to predict the probability of Bionano Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionano Genomics' price. Additionally, you may evaluate how the addition of Bionano Genomics to your portfolios can decrease your overall portfolio volatility.

	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Stocks Directory Find actively traded stocks across global markets

Is Bionano Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(6.81)

Revenue Per Share

1.058

Quarterly Revenue Growth

0.305

Return On Assets

(0.33)

Return On Equity

(1.35)

The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bionano Genomics Stock Total Asset

Bionano Genomics Company Total Asset Analysis

Total Asset

Tangible Assets

+

Intangible Assets

Current Bionano Genomics Total Asset

Bionano Total Asset Driver Correlations

Bionano Total Asset Historical Pattern

Bionano Total Assets

Total Assets

142.92 Million

Bionano Total Asset Peer Comparison

Bionano Genomics Institutional Holders

Bionano Fundamentals

About Bionano Genomics Fundamental Analysis

Pair Trading with Bionano Genomics

Moving together with Bionano Stock

Moving against Bionano Stock

Complementary Tools for Bionano Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY